Melbourne, Florida (PRWEB) September 11, 2014

Central Florida board-certified veterinary surgeon, Jeffrey S. Christiansen is proud to announce his partnerships with several Brevard County animal hospitals to bring regenerative veterinary medicine to pets. Dr. Christiansen has been working in the area since January 2006, credentialed to do stem cell therapy on small animals since 2008, and is happy to now offer his expertise through five different locations.

Over the years Dr. Christiansen has used stem cell therapy with Vet-Stem, Inc. on cruciate ligament and meniscus injuries, as well as osteoarthritis of the hips and other joints. Once Dr. Christiansen has identified a patient as a good stem cell therapy candidate, the pet undergoes a simple surgery to collect fat that is sent overnight to Vet-Stems lab in California. The day after the collection the fat is processed so stem cells can be extracted and put into concentrated, injectable doses. These doses are shipped back overnight to Dr. Christiansen and he is able to place them in the affected areas of the patient to encourage healing and regeneration.

Even if a pet is not an immediate candidate for stem cell therapy, but is undergoing an orthopedic or other type of surgery with Dr. Christiansen, he offers the ability to collect a small sample of fat for future stem cell use with Vet-Stem. Vet-Stem has the ability to cryo-bank stem cells and grow them in the future to provide doses when needed. This service is called StemInsure for dogs, and provides the insurance of a pet having a lifetime of stem cell therapy available from a single sample collection.

Stem cell therapy can be an alternative for pets that are unable to take anti-inflammatories or have digestive issues, as well as pets that are looking at long-term pain management. Because the stem cells come directly from the patient risk is low, and the procedure is natural.

As part of Superior Veterinary Surgical (and less-invasive) Solutions, Dr. Christiansen will be offering stem cell therapy at the following clinics beginning in September: Island Animal Hospital in Merritt Island, Brevard Animal Emergency Hospital in Malabar, Aloha Pet and Bird Hospital in Indian Harbour, Maybeck Animal Hospital in West Melbourne, and the Animal Emergency and Referral Center in Fort Pierce. He is bringing nearly 20 years of veterinary medicine experience with him, and takes pride in specializing in soft tissue, orthopedic, and spinal surgery.

About Dr. Christiansen and Superior Veterinary Surgical Solutions Jeffrey S. Christiansen, DVM, DACVS graduated from the University of Tennessee College of Veterinary Medicine in 1996. He completed his surgical residency in 2001, following an internship, and in 2002 he became a Diplomate of the American College of Veterinary Surgeons. Dr. Christiansen has been practicing in Brevard County since the beginning of 2006 and runs Superior Veterinary Surgical Solutions. In addition to stem cell therapy, some special areas of interest to Dr. Christiansen include artificial urethral sphincter (for incontinence), juvenile pubic symphysiodesis (for prevention of arthritis secondary to hip dysplasia), prophylactic gastropexy (for prevention of gastric dilatation-volvulus, commonly referred to as bloat), subcutaneous ureteral bypass (for obstructions between the kidney and bladder in cats), ureteral stenting (for obstruction between the kidney and bladder in dogs), and urethral stenting (for urethral obstruction), tibial tuberosity advancement (for tears of the cranial cruciate ligament; ACL in people) and tracheal stenting (for tracheal collapse).

About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read the original post:

Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond

TIME Health medicine Woman Receives First Stem Cell Therapy Using Her Own Skin Cells A Japanese woman is the first to receive retinal cells made from her own skin cells

Researchers at the RIKEN Center for Developmental Biology in Japan surgically transplanted a sheet of retinal pigment cells into the eye of a 70-year old woman on Friday.

The cells are the first induced pluripotent stem cells, or iPS cells, given to a human patient. They were made by Masayo Takahashi, who grew them from the patients own skin cells, which were treated with four genetic factors to revert back to an embryonic-like state. Takahashi then soaked the cells with the appropriate growth factors and other compounds so they developed into retinal pigment cells.

The patient was losing her sight due to macular degeneration, because her retinal pigment endothelial cells were damaged by an overgrowth of blood vessels. Replacing them with a new population of cells can restore her sight.

MORE: Stem-Cell Research: The Quest Resumes

Stem cell scientists are starting to test their treatments in eye-related diseases, because parts of the eye are protected from the bodys immune system, which could recognize the introduced cells as foreign and destroy them. Thats not a problem with the iPS cells, since they are made from the patients own skin cells, but its an added safety net to ensure that the therapy is safe and hopefully effective.

Because iPS cells are genetically treated to erase their skin cell development and revert them back to an embryonic-like state when they can become any type of cell, there are still concerns about their safety when transplanted into patients. The U.S. Food and Drug Administration has not yet approved a trial involving iPS cells so far, only stem cells made from excess IVF embryos have been approved for treating macular degeneration. A 19-member committee of the Japanese ministry of health approved the experimental procedure four days ago, according to Nature, after Takahashi made her case, with the help of Dr. Shinya Yamanaka of Kyoto University, who shared the 2012 Nobel Prize for discovering iPS cells.

MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions like Alzheimers

Japans stem cell scientists are hoping the surgery is a success; the field has been struggling since a well-publicized paper about a new way to make iPS cells was retracted amid allegations of fraud.

Its not known whether the cells will continue to grow and form abnormal tumors, or whether they will migrate to other parts of the body. But now that the first patient has received them, those questions and more, about the effectiveness of stem cell therapy might be answered soon.

Read more from the original source:

Woman Receives First Stem Cell Therapy Using Her Own Skin Cells

Stem cell therapy is one way thegovernments preparing for a nationimpacted by nuclear disaster.

Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield- a portion of the Bush-era War on Terror that medically readies the nation against chemical, biological, radiological or nuclear attacks.

This is part of a $163.8 million commitment from theBiomedical Advanced Research and Development Authority, or BARDA.

The new dollars will go toward San Carlos, California-based Cellerants Phase 2 trial in patients with acute myeloid leukemia, as well as the preclinical trials to treat radiation poisoning, or Acute Radiation Syndrome.

As it relates toradiation poisoning, Cellerant said its drugCLT-008 is meant to provide hematopoietic support after exposure to ionizing radiation such as from a nuclear or radiological weapon, or from a nuclear accident, it said in a statement.

The privately held company also recently wrapped up early-stage clinical studies in patients with acute myeloid leukemia, as well as in patients that are undergoing an umbilical cord blood transplant. Cellerant found CLT-008, was safely tolerated in 75 patients, it said in a statement. Its Phase 2 is testing for a decrease in risk of febrile neutropenia, and infections stemming from chemo.

CLT-008 is essentially a collection of deep-freezed stem cells that can ultimately defrost and mature into working granulocytes, platelets and red blood cells in a person. In nonclinical models, Cellerant has shown that the treatments highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival.

Get our daily newsletter or follow us.

Please enter your email below:

View post:

Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

San Antonio, TX (PRWEB) September 11, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.

Stem Cell Institute Speakers include:

Neil Riordan PhD Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special Guest Speaker:

Janet Vaughan, DDS, MS, Professional Dancer- Successful Stem Cell Therapy in Panama: A Patients Perspective

Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.

Read the original:

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.

The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.

Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.

Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.

Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.

This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.

This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.

See the original post:

Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

'So far appears safe, without side effects'

(ANSA) - Boston, September 9 - Mesenchymal stem cell therapy to treat multiple sclerosis so far appears safe and without side effects, according to data released Tuesday and obtained through clinical trials on patients as part of the international Mesems project coordinated by University of Genoa neurologist Antonio Uccelli. The results were announced ahead of the World Congress on Treatment and Research in Multiple Sclerosis opening in Boston Wednesday through Saturday. The Mesems project involves researchers from nine countries - Italy, Spain, France, Britain, Sweden, Denmark, Switzerland, Canada and Australia. It is the first large phase II international multicentre clinical trial to determine the safety of a consensus treatment protocol established by the International Mesenchymal Stem Cells Transplantation Study Group to obtain information on its effectiveness on multiple sclerosis patients. So far, 81 patients have been involved in the project - half of the 160 needed for the whole clinical trial. About 73 - or 90% of those involved in blind testing - were given at least one injection with mesenchymal therapy or got a placebo while 51 - or 63% - were given both injections and 27 - 33% - completed the study. "The promising result is that so far none of these 27 people have suffered significant adverse events, which means that, so far, the treatment appears to be safe", said Uccelli. The neurologist warned that "caution is necessary" and that the effectiveness of the therapy can only be determined once the study is completed in 2016. Uccelli however added that preliminary studies on animals have persuaded researchers that mesenchymal stem cells "can halt inflammation on the central nervous system and probably succeed in protecting nervous tissue, even repairing it where damage is minor". Out of the 81 patients recruited so far, "28 are Italian and 10 of them have completed the study", Uccelli said, adding that all patients over the past year did relatively well except for one who was treated with placebo. The neurologist expressed the hope that "data in 2016 will give final confirmation that the therapy is effective so we can take the subsequent step with a larger phase III study aimed at demonstrating the role of stem cells as neurorepairers". Meanwhile Genoa's bioethics committee has approved a two-year extension of the project, which will be called Mesems Plus, "to verify, beyond the year of observation provided for by Mesems, the long-term safety of treatments in the study and the potential insurgence of adverse events in all those treated", said Uccelli.

The rest is here:

MS stem-cell breakthrough led by Italians

Wichita, KS (PRWEB) September 09, 2014

Twenty-eight year-old Ryan Benton has lived with Duchenne Muscular Dystrophy his entire life. In 2009, he was fortunate enough to begin receiving adult stem cell treatments at the Stem Cell Institute in Panama City, Panama. These treatments have had a dramatic impact on Ryan by increasing his muscle strength, enhancing his sense of well being and improving his overall outlook on life.

After receiving his first stem cell treatments, Ryan, along with his siblings Lauren and Blake, recognized that very few people knew much about adult stem cell therapy. So together, they founded Coming Together for a Cure (CTFAC) as a means to raise awareness and funds. Their ultimate goal is to afford others the same opportunity that Ryan has been fortunate enough to receive.

Our family has been extremely blessed by having the opportunity for Ryan to receive adult stem cell treatments. The treatments have given him more strength, balance, endurance and an overall better physical wellbeing. By having this opportunity we hope to share awareness of adult stem cell therapy so that other families can benefit from this advancement in medicine as we have, said Sandra Renard, Ryans mother.

The annual Coming Together for a Cure benefit has grown tremendously over the years. At this years 6th annual event on Saturday September 13th, CTFAC is anticipating its largest crowd ever, of up to 1,000 attendees.

The venue, known as The Farm, is located at 5820 N. Ridge Rd. Wichita, KS 67205. Doors open to the general public at 6:00pm. Starting at 6:30, guests will be treated to live music and entertainment from classic rock, bluegrass and country music bands. Music from Kansas native and current Nashville recording artists, Jared Daniels Band starts at 8:30. Refreshments, concessions, adult beverages and food trucks will also be on hand.

Over the past five years the annual Coming Together for a Cure benefit has raised nearly $60,000. Money raised at each CTFAC event is donated to the Aidan Foundation, a 501(c)(3) non-profit organization founded by renowned stem cell scientist, Neil Riordan, PhD. The Aidan Foundation has funded Ryans treatments since 2009 and continues to provide ongoing funding.

Ryans father George Benton said, Ryan's stem cell treatment has truly become a dream come true. This dream was made possible by our wonderful friends and family who have generously given their talents, their love, and their financial support to Ryan in his quest for a cure. This effort proves that together, we can do anything.

CTFAC Contact Information:

Email: comingtogetherforacure(at)gmail(dot)com Website: comingtogetherforacure.org Facebook: http://www.facebook.com/comingtogetherforacure Twitter: @CTFACbenefit

See the rest here:

Coming Together For A Cures 6th Annual Benefit for Duchennes Muscular Dystrophy in Wichita, Kansas On Saturday ...

Father-of-two James Cross, 55, suffered a heart attack in February Surgeons at the London Chest Hospital offered him a unique chance Experimental therapy involved injecting stem cells from Mr Cross's hip into his heart in the hope they would encourage the organ to repair itself It appears to have worked as Mr Cross's heart muscle function has increased from 21% after the attack to 37% and it is still improving Experts hope the new technique will increase survival rates by a quarter

By John Naish

Published: 20:38 EST, 8 September 2014 | Updated: 07:12 EST, 9 September 2014

James Cross, 55,was offered experimental treatment after suffering a heart attack in February

After James Cross had a heart attack in February, he was given a unique chance for a new life.

Surgeons at the London Chest Hospital offered the 55-year-old experimental therapy that involved injecting his own stem cells into the damaged organ.

This was done in the hope that it would encourage his heart to repair itself.

The injected stem cells should prevent the hearts muscle tissue from becoming increasingly damaged after suffering a lack of oxygen during the heart attack.

And it seems to have worked.

After the heart attack, I had 21 per cent of my heart muscle functioning, as opposed to the normal 61 per cent, says James.

See the rest here:

Could stem cells from your hip repair your heart after an attack?

Freeport, Grand Bahama (PRWEB) September 08, 2014

Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified heart disease candidates. The procedure will be performed in their newly constructed state-of-the-art Phillips catheterization lab, as announced last month.

Just 50 miles from US shore, Okyanos cardiac cell therapy is available to qualified patients with advanced stages of coronary artery disease (CAD) and congestive heart failure (CHF). The screening process consists of a thorough review of your medical history by the Okyanos Chief Medical Officer and Cardiologist, Dr. Howard Walpole, as well as consultation done in conjunction with your cardiologist. You must be able to travel as the protocol is delivered in Freeport on Grand Bahama Island.

"As a leader in cardiac cell therapy, Okyanos is very excited to bring this innovative treatment and new standard of care to patients in a near-shore, regulated jurisdiction, said Matt Feshbach, CEO and co-founder of Okyanos. Our innovative treatment will restore blood flow to the heart helping it begin the process of healing itself, thereby improving the quality of life for heart disease patients who have exhausted all other options.

Over 12 million Americans suffer from some form of heart disease costing $108.9 billion dollars annually in the US alone. Several million patients have now exhausted the currently available methods of treatment but continue to suffer daily from chronic heart disease symptoms such as shortness of breath, fatigue and chest discomfort that can make simple activities challenging. Cardiac cell therapy stimulates the growth of new blood vessels which can lead to reduced angina and reduced re-hospitalizations resulting in an improvement in quality of life.

The Okyanos procedure is performed by prestigious US-licensed chief cardiologist, Dr. Howard Walpole. It is the first cardiac cell therapy procedure for heart failure and disease available outside of clinical trials in which the bodys own adult stem cells, derived from fat tissue, are injected directly into the damaged part of the heart via a catheter to restore blood flow and repair tissue damaged by a heart attack or disease.

The procedure begins with the extraction of a small amount of your body fat, a process done using advanced water-assisted liposuction technology. After separating the fat tissue using a European Union-approved cell processing device the Okyanos cardiologist immediately injects these cells into and around the low blood flow regions of the heart via a cathetera protocol which allows for better targeting of the cells to repair damaged heart tissue. Because the treatment is minimally invasive it requires that patients be under only moderate sedation. Post-procedural recovery consists of rest in a private suite for several hours that comfortably accommodates up to 3 family members.

Okyanos Heart Institute is scheduled to begin delivery in the next several weeks. Patients can contact Okyanos at http://www.Okyanos.com or by calling toll free at 1-855-659-2667.

About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by CEO Matt Feshbach and Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow.

More:

Okyanos Cardiac Cell Therapy Clinic Scheduled to Open

Beverly Hills, California (PRWEB) September 08, 2014

Beverly Hills Orthopedic Institute has become an R3 Stem Cell Center of Excellence. Patients are immediately able to benefit from the regenerative medicine procedures at the Center, including bone marrow or amniotic derived stem cells for arthritis, sports injuries, and all types of chronic pain issues. Call R3 Stem Cell for scheduling at (844) GET-STEM.

R3 Stem Cell works with the best Board Certified providers nationwide, bringing the latest cutting edge regenerative medicine procedures to those in need. The top Beverly Hills orthopedic surgeon, Dr. Raj, is the medical director of Beverly Hills Orthopedic Institute and has performed over 50 stem cell procedures to date. Patients have include elite athletes, celebrities, executives, students, manual laborers and senior citizens. In other words, every walk of life can benefit.

The procedures offered include stem cell therapy for arthritis, back pain, cartilage defects, tendonitis, migraines, fracture healing and ligament injuries. The procedures are often able to help patients avoid the need for surgery and provide excellent pain relief with increased function.

Said R3 CEO Bob Maguire, MBA, Dr. Raj is a highly respected, skilled and compassionate provider who is committed to providing cutting edge options to his patients. It can help them heal faster while achieving pain relief. Thats what R3 Centers of Excellence strive for and have been very successful with to date.

Several different types of regenerative medicine procedures are offered at the R3 Center of Excellence. Amniotic stem cell procedures have shown amazing benefits in small studies to date. The fluid is obtained from consenting donors after a scheduled c-section, with the material being processed at an FDA regulated lab. No fetal tissue is involved or embryonic stem cells.

Bone marrow aspirate stem cell therapy is also offered, with the same day procedure injecting the processed bone marrow into the problem area. A high concentration of stem cells and growth factors sparks an impressive healing process, which can often regenerate damaged tissue.

Platelet rich plasma therapy is also offered, which involves a simple blood draw from patients. Studies are beginning to show that the regenerative medicine procedures work well for helping patients avoid the need for joint replacement surgery and also assisting athletes to get back on the field faster than otherwise.

Financing is available for the procedures at all R3 Stem Cell Centers of Excellence. Call (844) GET-STEM for more information and scheduling with stem cell treatment Los Angeles trusts.

See original here:

Beverly Hills Orthopedic Institute Becomes R3 Stem Cell Center of Excellence

Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases
Stem Cell Therapy with Mesenchymal stem cells are pluripotent and adult cells with fibroblastoid morphology and plasticity, toward various cell lineages such as chondrocytes, osteocytes and...

By: enjades

Originally posted here:

Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases - Video

From the perspective of a community physician, the stem cell research, at this point, is not a priority. Given the daunting task of not only curing the present crop of diseases but also preventing them, and of course, building the human resource as the backbone of the health care system these should be the priority. Joseph Carabeo, convenor, Rx Abolish Pork Barrel Movement

By ANNE MARXZE D. UMIL Bulatlat.com

MANILA Eleazar Sobinsky, president of the Lung Center of the Philippines Employees Association-Alliance of Health Workers cannot decipher how the Disbursement Acceleration Program (DAP) has helped the poor. Of the P115 million ($263,822) DAP funds received by LCP, P70 million ($160,587) was spent for the stem cell research project and the rest was spent for the procurement of equipment.

He said if the DAP has helped the poor, why are there more indigent patients waiting in line at the LCPs out-patient department?

Joseph Carabeo, convenor of the Rx Abolish Pork Barrel Movement and a community doctor for the past 28 years, said that the stem cell research project does not even help solve the longtime health problems of Filipinos.

The stem cell research in LCP is a mispriority, said Carabeo in an interview with Bulatlat.com. There are many problems in the health sector that has to be addressed. We think, the DOH is merely riding the bandwagon on the stem cell research intervention in health care, wellness and primarily rejuvenation, Carabeo said.

(Photo by Ronalyn V. Olea / Bulatlat.com)

Stem cells according to http://www.stemcellnetwork.ca are the precursors of all cells in the human body.

Stem cells are very special, powerful cells found in both humans and non-human animals. They have been called the centerpiece of regenerative medicine medicine that involves growing new cells, tissues and organs to replace or repair those damaged by injury, disease or aging, the website said.

In the Philippines, Carabeo said, the medical community is not even united in the use of stem cell therapy in curing diseases. He said it is still under research in the Philippines. The Philippine Society of Endocrinology and Metabolism (PSEM) for one has even warned the public on the use of stem cell therapy as treatment for diabetes.

Read more from the original source:

DAP-funded stem cell research a wrong priority

Lung Institute-Patient Testimonial, Mike K., Leesburg, FL
Mike K., 71, from Leesburg, FL, came to the Lung Institute for treatment of his asthma. Since stem cell therapy, Mike visits the gym four times a week and can jog over a quarter of a mile where...

By: Lung Institute

See the original post:

Lung Institute-Patient Testimonial, Mike K., Leesburg, FL - Video

Stem Cell Therapy Testimonial
Arthritis Stem Cell Therapy Testimonial. Dr. Lox can be reached at http://www.drloxstemcells.com or Call (844) 440-8503 for information on Stem Cell Therapy.

By: Dr. Lox

Read the original post:

Stem Cell Therapy Testimonial - Video

La Jolla, CA (PRWEB) September 03, 2014

A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.

Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.

Clinical studies for stem cell treatment are currently being offered by StemGenex to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof, said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.

StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinsons Alzheimers disease, and others. Rita Alexander, founder of StemGenex and the companys first stem cell patient, insists that all patients be treated like they are one of our loved ones. Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

Continue reading here:

Latest Study on Stem Cell Therapy Shows Promising Signs of Recovery for Stroke Patients and Support for StemGenex ...

The treatment involves injecting up to 20 million stem cells into patients' brains. It was tested on patients at Glasgow's Southern General Hospital in 2012.

The Surrey-based company said it would work at 10 sites across the UK, including the Southern General, on a Phase II efficacy study of the ReN001 treatment involving 41 patients.

Loading article content

The treatment is designed to deliver a meaningful improvement in upper limb function in disabled stroke patients.

In May, the company said data from a long-term follow- up involving 11 patients included in a Phase I safety study of ReN001 at the Glasgow hospital observed sustained reductions in neurological impairment and spasticity in most patients. No cell-related or immunological adverse events were reported .

Yesterday, Reneuron said it has also started a Phase I safety study at Ninewells Hospital in Dundee of its ReN009 therapy for people with lower limb ischaemia. It will involve nine patients.

Reneuron says the disease is common in patients with diabetes and can lead to amputation of the limb.

Link:

Reneuron tests stem cell stroke treatment

ReNeuron Group Quote more

Price: 3.62

Chg: -0.19

Chg %: -4.87%

Date: 16:38

Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials.

The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun.

The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year.

Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months.

"In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said.

Read more here:

Reneuron on track for clinical milestones as studies get underway

Sep 01, 2014 The biobank comprises three cryotanks, equipped with cooled protective hoods, and a transfer station from which the sample containers are transported via a rail system. There is enough space for approximately 60,000 samples. Credit: Fraunhofer IBMT

For the development of new drugs it is crucial to work with stem cells, as these allow scientists to study the effects of new active pharmaceutical ingredients. But it has always been difficult to derive enough stem cells of the right quality and in the right timeframe. A central biobank is about to remedy the situation.

Human stem cells allow scientists to assess how patients are likely to respond to new drugs and to examine how illnesses come about. For a few years now, it has been possible to take tissue samples from adults and use reverse programming to artificially produce stem cells, which have the potential to create any kind of cell found in the human body. Before this discovery, pharmaceutical researchers had to use adult stem cells or primary cells, which have a more limited potential. Another option is to use stem cells derived from human embryos, but quite apart from the ethical considerations these cells are available only in limited diversity. The new technique makes it possible for instance to reprogram adult skin or blood cells so that they behave in a similar way to embryonic stem cells and can become any type of cell. "These are known as induced pluripotent stem cells, or iPS cells for short," says Dr. Julia Neubauer from the Fraunhofer Institute for Biomedical Engineering IBMT in St. Ingbert, Germany. Although an increasing number of local biobanks have emerged in recent years, none of them fulfills the requirements of the pharmaceutical industry and research institutions. What is needed is a supply of 'ready-to-use' stem cells, which means large numbers of consistently characterized, systematically catalogued cells of suitable quality.

At the beginning of 2014, the IBMT teamed up with 26 industry and research partners to launch a project aimed at establishing a central biobank the European Bank for induced pluripotent Stem Cells (EBiSC) to generate iPS cells from patients with specific diseases or genetic mutations (http://ebisc.org/). Six months into the project and the first cells are available for use in the development of new drugs. By its three-year mark, it is hoped the project will be in a position to offer over 1000 defined and characterized cell lines comprising a hundred million cells. Such quantities are needed because a single drug screening involves testing several million cells. The main biobank facility is being built in the English city of Cambridge and an identical "mirror site" will be set up at the IBMT's Sulzbach location in Germany.

Gently freezing cells

The IBMT was brought on board for EBiSC by virtue of the comprehensive expertise it gained through participation in the EU's "Hyperlab" and "CRYSTAL" projects. For EBiSC, IBMT scientists are responsible for freezing the cells and for automating cell cultivation and the biobank itself. For an efficient long-term storage of functional stem cells, they have to be cooled down to temperatures of below 130 degrees Celsius in a controlled way. The scientists have to prepare the cells so they can survive the cold shock of nitrogen gas. The IBMT has, for instance, developed technologies that allow cells to be frozen in an extremely gentle way. "Cells don't like being removed from the surface they are grown on, but that's what people used to do in order to freeze them. Our method allows the cells to stay adherent," explains Neubauer.

Just as with foodstuffs, stem cells depend on an unbroken cold chain to preserve their functionality and viability. The scientists store the cells in special containers or cryotanks each measuring one by two meters. To remove a particular sample, the scientists have to open the cryotank. The problem is that this exposes all the other samples to warmer ambient air, causing them to begin to thaw out. "It's just like when you go to your refrigerator at home it's not a good idea to leave the door open too long," says Neubauer. She and her colleagues at the IBMT and industry partner Askion GmbH have together developed a stem cell biobank complete with protective hoods that protect the other samples whenever the cryotank is opened. In addition to maintaining the temperature, the hoods help keep another key shelf-life criterion, humidity, at a constant level.

Flawless freezing is important, but it is just as important to automate the whole process. "That not only guarantees consistency, it's what makes it possible to provide large quantities of cells of the required quality in the first place," says Neubauer. And the scientists' cooling process already boasts a finished technology. In their automated biobank, each cell sample is labelled with barcodes to allow them to be tracked. The samples travel along a conveyor belt to the individual cyrotanks, and a computer monitors the entire freezing and storage process.

Now the scientists are working on automating cell cultivation or the multiplying of the cells. There are essentially two possible approaches. One is to use robots that translate each preparation step into a mechanical one. The other is to use stirred bioreactors that provide free-moving cells with the ideal supply of nutrients and oxygen. Both technologies feature in the IBMT's portfolio. "By the time the project is completed, we'll know which is the better method for what we're trying to do," says Neubauer.

Explore further: Animal-free reprogramming of adult cells improves safety

See more here:

Central biobank for drug research

Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-much-does-stem-cell-therapy-cost/ Find out about how much stem cell therapy will cost you...

By: Thanyapura Health Centre

Follow this link:

Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost - Video

Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-is-your-stem-cell-therapy-different/ Thanyapura Health offers natural stem cell activation,...

By: Thanyapura Health Centre

Here is the original post:

Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different - Video